Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs

January 28, 2019

OBE022

Simon Coates, Oliver Pohl, Jean-Pierre Gotteland, Jörg Täubel, Ulrike Lorch

Article first published online: January 27, 2019

Coates S, Pohl O, Gotteland JP, Täubel J, Lorch U. Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs. Ther Innov Regul Sci. 2020;54(1):184‐194. doi:10.1007/s43441-019-00044-y

Read more

A Placebo-Controlled, Randomized, Double-Blind, Phase 3 Study Assessing Ongoing Pregnancy Rates After Single Oral Administration of a Novel Oxytocin Receptor Antagonist, Nolasiban, Prior to Single Embryo Transfer

October 9, 2018

Nolasiban

Visnova H., Tournaye H. J., Humberstone A., Terrill P., Macgregor L., Loumaye E.

ASRM 2018, 6-10 October 2018, Denver, CO

Fertility and Sterility September 2018 Volume 110, Issue 4, Supplement, Page e45, Abstract O101

Read more

Effects of the oral oxytocin receptor antagonist nolasiban on early embryonic development

July 4, 2018

Nolasiban

O. Pohl, D. Perks, R. Sisti, J.P. Gotteland

ESHRE Annual Conference, 01-04 July 2018, Barcelona, Spain
Abstract P-121 on Pages i196-i197

Abstract P-121 on Pages i196-i197 – Human Reproduction, Volume 33, Issue suppl_1, July 2018, Pages i1–i541,

Read more

OBE022, an oral and selective prostaglandin F2α receptor antagonist as an effective and safe modality for the treatment of preterm labor

May 18, 2018

OBE022

Pohl O, Chollet A, Kim SH, Riaposova L, Spezia F, Gervais F, Guillaume P, Lluel P, Meen M, Lemaux F, Terzidou V, Bennett PR, Gotteland JP.

Journal of Pharmacology and Experimental Therapeutics August 2018, 366 (2) 349-364; doi:10.1124/jpet.118.247668

Read more

Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women

April 30, 2018

OBE022

Pohl O, Marchand L, Gotteland JP, Coates S, Täubel J, Lorch U

Pohl O, Marchand L, Gotteland JP, Coates S, Täubel J, Lorch U. Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women. Br J Clin Pharmacol. 2018;84(8):1839‐1855. doi:10.1111/bcp.13622

Read more

ObsEva on page 17 of Understanding Fertility Special Report 2018

April 24, 2018

Nolasiban

Special report in the Raconteur Article in ‘The Times’ Click here for publication link IVF ‘BREAKTHROUGH’ TREATMENT Pioneering use of…

Read more

Effects of the Oral Prostaglandin F2 Alpha Receptor Antagonist Tocolytic OBE022 on Reproduction in Rats and Rabbits

March 10, 2018

OBE022

Oliver Pohl, Roberta Sisti, Jean-Pierre Gotteland

SRI Conference, 06-10 March 2018, San Diego, CA
Abstract S-037: page 265A

Reproductive Sciences Vol. 25, Supplement 1, March 2018 265A Abstract S-037

Read more

Safety and Pharmacokinetics of the Oral Prostaglandin F2 Alpha Receptor Antagonist Tocolytic OBE022: A First-in-Human Study in Healthy Women

OBE022

Oliver Pohl, Ulrike Lorch, Line Marchand, Jean-Pierre Gotteland

SRI Conference, 06-10 March 2018, San Diego, CA
Abstract S-038: Pages 265A-266A

Reproductive Sciences Vol. 25, Supplement 1, March 2018 265A-266A Abstract S-038

Read more

Confirmation of the Cardiac Safety of PGF2α Receptor Antagonist OBE022 in a First-in-Human Study in Healthy Subjects, Using Intensive ECG Assessments

February 28, 2018

OBE022

Jörg Täubel, Ulrike Lorch, Simon Coates, Sara Fernandes, Paul Foley, Georg Ferber, Jean-Pierre Gotteland, Oliver Pohl

Täubel, J., Lorch, U., Coates, S., Fernandes, S., Foley, P., Ferber, G., Gotteland, J.‐P. and Pohl, O. (2018), Confirmation of the Cardiac Safety of PGF2α Receptor Antagonist OBE022 in a First‐in‐Human Study in Healthy Subjects, Using Intensive ECG Assessments. Clinical Pharmacology in Drug Development, 7: 889-900. doi:10.1002/cpdd.447

Read more

GnRH Receptor Antagonist Mono- And Combination Therapy With E2/NETA Add-Back – Pharmacodynamics And Safety Of OBE2109

December 4, 2017

Linzagolix

Pohl O, Marchand L, Fawkes N, Gotteland JP, Loumaye E.

Pohl O, Marchand L, Fawkes N, Gotteland JP, Loumaye E. Gonadotropin-Releasing Hormone Receptor Antagonist Mono- and Combination Therapy With Estradiol/Norethindrone Acetate Add-Back: Pharmacodynamics and Safety of OBE2109. J Clin Endocrinol Metab. 2018;103(2):497‐504. doi:10.1210/jc.2017-01875

Read more